Table 1.

Structural and functional impairments are evaluated by analyzing Body Weight/Liver Weight ratio and ALT, AST, AP levels in serum samples of experimental liver fibrosis models. Body/Weight ratio of mice and ALT, AST and AP enzyme levels in serum samples were presented for healthy group (naïve); only Lipoxin A4-administered group (LXA4); following thioacetamide administration 3 via i.p route 3 days a week for 12 weeks in the liver fibrosis group (TAA), lipoxin A4 administered in a fibrotic mice group (TAA+LXA4) and healthy animals administered PBS (naïve+PBS) used for Lipoxin A4 dilution.

Group	Body Weight/Liver Weight	ALT (U/L) (15–84 U/L)¶	AST(U/L) (54–298 U/L)¶	AP (U/L) (35–96 U/L)¶
Naive	20.271±1.34	29.40±8.58	139.80±29.32	33.18±7.62
LXA4	18.869±2.36	36.60±12.45	109.20±14.26	87.12±9.48
TAA	15.916±1.73*	255.56±71.04#	247.87±33.38ŧ	151.95±14.44$
TAA+LXA4	16.263±3.44	77.40±13.74	169.50±14.13	132.93±17.57
Naive+PBS	21.476±2.13	26.22±3.84	128.31±18.56	42.15±5.58

^{*, # and ŧ}symbolize significant differences between the TAA and TAA+LXA4 group (p<0.05 for both evaluation).

^$symbolizes significant difference between the naive group and TAA group (p<0.05).

^¶Normal range of AST, ALT, and AP in serum of BALB/c mice (18).